Skip to content
MARK EGLY

AATD and Neurological Conditions

An emerging research area with careful labeling

By Mark Egly Foundation

Research hypothesis. Possible connections between Alpha-1 Antitrypsin Deficiency (AATD) and neurological conditions on this page reflect Mark Egly's patent research framing. They are not established medical fact and are not medical advice. Always talk with your doctor about your own health.

Why we publish this hub

Neurological conditions such as Alzheimer's disease, ALS, Parkinson's disease, and multiple sclerosis generate enormous search interest. Very little public content connects those topics to AATD. The Mark Egly Foundation can help patients and clinicians find hypothesis labeled education while they continue evidence based neurological care.

Established AATD education first

Start with proven AATD basics before reading research hypotheses:

Research framing

Mark's patent explores inflammation, neutrophil activity, and AAT levels across many organ systems, including neurological disease names in the catalog. Those inclusions signal research interest, not proven cause and effect.

Catalog pages to explore

Filter Diseases by Neurological, or open examples:

Related autoimmune neurological overlap may also appear under the Autoimmune filter. See AATD and autoimmune diseases.

What this is not

This hub does not diagnose neurological disease, does not replace neurology care, and does not claim AAT therapy treats Alzheimer's, ALS, Parkinson's, or MS.

Next steps

  1. Discuss symptoms with your clinician.
  2. Ask about AAT testing when lung or liver findings or family history raise the question.
  3. Read the patent overview for research context.
  4. Clinicians: AATD diagnosis and testing.
  5. Support research if you want more independent study in this space.